Ptc Therapeutics (PTCT) Tax Provisions (2015 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Tax Provisions of $14.0 million for Q2 2026, up 326.49% year-over-year from $3.3 million in Q2 2025, and up 3948.7% quarter-over-quarter from $347000.0 in Q1 2026.
Ptc Therapeutics (PTCT) Tax Provisions (2015 - 2026) Analysis & Trends
Ptc Therapeutics' Tax Provisions history runs 12 years deep, the most recent figure standing at $14.0 million for Q2 2026.
- In Q2 2026, Tax Provisions rose 326.49% year-over-year to $14.0 million; the TTM figure through Jun 2026 stood at $103.6 million (up 63.1% YoY), while the FY2025 annual figure was $146.3 million, up 445.9% from the prior year.
- Tax Provisions for Q2 2026 stood at $14.0 million, up from $347000.0 in the prior quarter.
- The five-year high for Tax Provisions was $128.2 million in Q4 2025, with the low at -$39.0 million in Q3 2025.
- The 5-year median for Tax Provisions is $1.9 million (2022), against an average of $5.0 million.
- The sharpest annual moves came in 2022 and 2025: Tax Provisions tumbled 49602.78% in 2022, then soared 5951.07% in 2025.
- Ptc Therapeutics' Tax Provisions stood at -$18.8 million in 2022, then jumped by 93.3% to -$1.3 million in 2023, then tumbled by 74.03% to -$2.2 million in 2024, then jumped by 5951.07% to $128.2 million in 2025, then tumbled by 89.04% to $14.0 million in 2026.
- Business Quant data shows PTCT's Tax Provisions at $14.0 million in Q2 2026, $347000.0 in Q1 2026, and $128.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 14.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.05 Mn |
| Mar 31, 2026 | 347,000.00 |
| Dec 31, 2025 | -13.70 Mn |
| Sep 30, 2025 | -38.97 Mn |
| Jun 30, 2025 | -6.20 Mn |
| Mar 31, 2025 | 63.27 Mn |
| Dec 31, 2024 | -2.19 Mn |
| Sep 30, 2024 | 8.66 Mn |
| Jun 30, 2024 | 13.45 Mn |
| Mar 31, 2024 | 6.88 Mn |
| Dec 31, 2023 | 41.02 Mn |
| Sep 30, 2023 | -33.62 Mn |
| Jun 30, 2023 | -38.60 Mn |
| Mar 31, 2023 | 3.97 Mn |
| Dec 31, 2022 | 13.89 Mn |
| Sep 30, 2022 | -17.89 Mn |
| Jun 30, 2022 | 3.39 Mn |
| Mar 31, 2022 | 4.84 Mn |
| Dec 31, 2021 | 436,000.00 |
| Sep 30, 2021 | -36,000.00 |